Moderna Inc. experienced a notable surge in its stock price, driven by positive market sentiment and strategic developments.
Shares of Moderna Inc. (NASDAQ:MRNA) went up yesterday by 4.81%, closing at CA$196.48. This increase comes as the healthcare sector gained traction in the market, reflecting a broader investor interest in biotech firms.
Advertisement
Moderna Inc
MRNA.US
MRNA.US
Moderna Inc
WealthAwesomeMarket cap
$78.65B
52W high
$212.22
52W low
$22.28
1W change
+4.27%
Beta
1.09
Analyst Price Targets
Based on 23 analysts covering MRNA · as of Oct 8, 2026
Wall Street analysts forecast MRNA stock price to fall 38.6% over the next 12 months.
Consensus
Hold3.17 / 5.00
Avg. Target
C$121.00
-38.6% Upside
Previously C$120.67 on Oct 5, 2026
Current Price
C$197.00
Last close
Analyst Breakdown (23 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MRNA's historical volatility
30-Day Vol
74.5%
Annualized
90-Day Vol
194.0%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$235.52
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$209.08 | C$161.68 – C$270.38 |
| 60 trading days | C$221.91 | C$154.26 – C$319.21 |
| 90 trading days | C$235.52 | C$150.88 – C$367.63 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors may find Moderna's recent price increase indicative of renewed confidence in the biotech sector, particularly with upcoming earnings reports and strategic collaborations in the pipeline.
4.81%
Moderna's stock price increase of 4.81% positions it as one of the top gainers in the healthcare sector, reflecting strong investor interest.
Bull case
The recent collaboration with Tempus to commercialize individualized cancer therapies shows Moderna's innovative approach and potential for future revenue growth. This partnership could boost investor sentiment as it highlights the company's commitment to advancing personalized medicine and capturing a larger share of the oncology market.
Bear case
Despite the positive movement, Moderna faces ongoing challenges, including a negative profit margin. These issues may raise concerns about its long-term financial stability and ability to seize new opportunities.
Market Sentiment Boosts Healthcare Stocks
Advertisement
The healthcare sector has been gaining momentum, with investors showing increased interest in biotech stocks like Moderna. The recent rise in stock price reflects a broader trend of optimism towards healthcare innovations and their potential market impact.
Strategic Collaboration with Tempus
Moderna's collaboration with Tempus to support the commercialization of individualized cancer therapies is a significant development. This partnership not only underscores Moderna's commitment to advancing personalized medicine but also positions the company to potentially capture a larger share of the oncology market.
Financial Considerations Ahead of Earnings
As Moderna approaches its upcoming earnings report, investors are keen to see how the company addresses its financial challenges, including a negative profit margin. The market's reaction to these earnings will be critical in determining the stock's trajectory moving forward.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
